Cost-Effectiveness Analysis of Multifocal Intraocular Lenses Compared to Monofocal Intraocular Lenses in Cataract Surgery.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
12 2019
Historique:
received: 01 12 2018
revised: 11 03 2019
accepted: 13 03 2019
pubmed: 25 3 2019
medline: 28 3 2020
entrez: 26 3 2019
Statut: ppublish

Résumé

To determine the cost-effectiveness of multifocal intraocular lenses (IOLs) compared to that of monofocal IOLs from a societal and health care sector perspective. Cost-effectiveness analysis. A Markov model was constructed that simulated patients who received either multifocal or monofocal IOLs during cataract surgery. Postoperatively, patients could experience spectacle dependence, glare, and haloes. Cost-effectiveness was determined by measuring the incremental cost-effectiveness ratio (ICER) as the incremental cost in dollars per quality-adjusted life year (QALY) gained. Treatments with an ICER below the standard willingness-to-pay (WTP) threshold of $50,000/QALY were considered cost effective. One-way sensitivity analyses and probabilistic sensitivity analyses were used to evaluate model sensitivity to cost, utilities, and other model inputs. Multifocal IOLs were associated with a 0.71 QALY increase at an increased cost of $3,415 compared with monofocal IOLs, leading to an ICER of $4,805/QALY from the societal and health care sector perspectives. The cost-effectiveness model was most sensitive to patient age, probability of spectacle dependence with multifocal IOLs and monofocal IOLs, and the disutility of glasses. Probabilistic sensitivity analysis found multifocal IOLs to be the cost-effective option compared with monofocal IOLs 99.9% of the time at a WTP threshold of $50,000/QALY. From a societal and health care perspective, multifocal IOLs would be considered a cost-effective strategy compared to monofocal IOLs for patients who desire a higher chance to be spectacle-free. However, more studies need to be conducted to further evaluate the efficacy of multifocal IOLs.

Identifiants

pubmed: 30905724
pii: S0002-9394(19)30125-4
doi: 10.1016/j.ajo.2019.03.019
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

305-312

Subventions

Organisme : NCATS NIH HHS
ID : TL1 TR001443
Pays : United States

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Jenny Q Hu (JQ)

Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.

Reith Sarkar (R)

Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA; and the Clinical and Translational Research Institute, University of California San Diego, La Jolla, California, USA.

Ruti Sella (R)

Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.

James D Murphy (JD)

Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA; and the Clinical and Translational Research Institute, University of California San Diego, La Jolla, California, USA.

Natalie A Afshari (NA)

Shiley Eye Institute, University of California San Diego, La Jolla, California, USA. Electronic address: naafshari@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH